Saturday, 31 Jan 2026
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • House
  • VIDEO
  • ScienceAlert
  • White
  • man
  • Trumps
  • Watch
  • Season
  • Years
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Economy > Regeneron (REGN) Draws Higher Target From TD Cowen
Economy

Regeneron (REGN) Draws Higher Target From TD Cowen

Last updated: January 31, 2026 2:05 pm
Share
Regeneron (REGN) Draws Higher Target From TD Cowen
SHARE

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has recently been recognized as one of the 13 Companies that Just Started Paying Dividends. The company, led by CEO Leonard Schleifer, reported steady revenue growth during the Q4 2025 earnings call. Fourth-quarter sales increased by 3% compared to the previous year, driven by double-digit growth in three key products.

Global net sales of DUPIXENT surged by 32%, while LIBTAYO sales saw a 13% increase on a constant-currency basis. In the U.S., EYLEA HD sales stood out with a remarkable 66% growth. Schleifer highlighted the strong performance of these products, especially in the domestic market, signaling positive momentum for the company.

DUPIXENT, described as a core pillar of the business, is now being used by over 1.4 million patients worldwide and is poised for further growth. Progress at LIBTAYO was also emphasized, with strength in adjuvant CSCC and a growing market share in advanced non-small cell lung cancer. In the U.S., the therapy has become the second most prescribed immunotherapy in the first-line setting.

Looking ahead, Schleifer outlined an ambitious regulatory and development agenda for Regeneron Pharmaceuticals. The company anticipates at least four FDA approvals, including three new molecular entities across different modalities, as well as approval of the EYLEA HD prefilled syringe. Additionally, plans are in place to launch 18 additional Phase III studies over the coming years, with an estimated total enrollment of around 35,000 patients. This significant investment aims to support the development of potential blockbuster products in the future.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a leading biotechnology company that focuses on inventing, developing, manufacturing, and commercializing medicines for individuals with serious diseases.

See also  ‘MAGA Over Jesus’: JD Vance Draws Damning Moral Rebuke From Catholic Newspaper

While Regeneron shows promise as an investment opportunity, some experts believe that certain AI stocks may offer greater upside potential with lower downside risk. For investors seeking an undervalued AI stock that could benefit from current economic trends, a free report on the best short-term AI stock is available.

In conclusion, Regeneron Pharmaceuticals continues to make strides in the biotechnology industry with its innovative products and strategic development plans. Investors should keep an eye on the company’s future advancements and potential growth opportunities.

Disclosure: None.

TAGGED:CowendrawshigherRegeneronREGNTarget
Share This Article
Twitter Email Copy Link Print
Previous Article Our verdict on Annie Bot: This novel about a sex robot split opinions Our verdict on Annie Bot: This novel about a sex robot split opinions
Next Article LI teen in botched murder-suicide is too loony to stand trial for at least a year: judge LI teen in botched murder-suicide is too loony to stand trial for at least a year: judge
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

OG MW2 one-shot meta sniper is back in Warzone

The recent Warzone Season 4 Reloaded update has brought about significant changes to the game,…

July 9, 2025

President Donald J. Trump Adjusts Tariffs on Canada and Mexico to Minimize Disruption to the Automotive Industry – ]

President Donald J. Trump announced adjustments to tariffs on imports from Canada and Mexico in…

March 6, 2025

Steadfast lifestyle changes seem best to improve cognitive decline

Regular exercise, along with a healthy diet, cognitive challenges, and social engagement, has been shown…

July 28, 2025

Hydrogen Isn’t as Climate-Friendly as We Thought, Concerning Study Finds : ScienceAlert

Is Hydrogen Really as Climate-Friendly as We Thought? Hydrogen has long been hailed as a…

December 18, 2025

5.9 Million Viewers Watched Season 27 Premiere

The highly-anticipated Season 27 premiere of "South Park" has proven to be a massive success…

July 30, 2025

You Might Also Like

Oracle (ORCL) Remains a Long-term Cloud Computing Story Despite Near-Term Headwinds
Economy

Oracle (ORCL) Remains a Long-term Cloud Computing Story Despite Near-Term Headwinds

January 31, 2026
Average car payments in 2025: What to expect
Economy

Average car payments in 2025: What to expect

January 31, 2026
Is This Small-Cap Growth ETF a Buy After Lee Financial Scooped Up Shares Worth Nearly  Million?
Economy

Is This Small-Cap Growth ETF a Buy After Lee Financial Scooped Up Shares Worth Nearly $8 Million?

January 31, 2026
Planet Labs PBC Director Sells 47K Shares Worth Over  Million
Economy

Planet Labs PBC Director Sells 47K Shares Worth Over $1 Million

January 31, 2026
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?